US · Healthcare · Biotechnology
EPS came in at -1.97 against a street estimate of -1.47 — a miss of 34.0%.
Analysts rate Vaxcyte Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $109.00.
| Fund | Stake |
|---|---|
| HHG PLC | 11.14% |
| FMR Inc | 11.08% |
| T. Rowe Price Investment Management,Inc. | 8.15% |
| RA Capital Management, LLC | 7.71% |
| BlackRock Inc | 7.37% |
| Wellington Management Company LLP | 4.71% |
| Vanguard Portfolio Management, LLC | 4.22% |
| Vanguard Capital Management, LLC | 4.21% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 VAXCYTE, INC. - FORM 8-K SUMMARY Report Date: August 31, 2026 | Filed: September 3, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Company: Vaxcyte, Inc. | 2026-09-03 |
| Quarterly report · Q2 2026 VAXCYTE, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $183.2 million cash and cash equivalents as of June 30, 2026 (vs. $174.0 mill | 2026-08-05 |
| Results announced · Q3 2026 VAXCYTE Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $2,507.7 million as of June 30, 2026 (up from $ | 2026-08-05 |
| Board / officer change · Q3 2026 VAXCYTE, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Vaxcyte, Inc. is a biopharmaceutical company incorporated in Delaware, trading on N | 2026-07-15 |
| Board / officer change · Q2 2026 VAXCYTE, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Vaxcyte, Inc. is a Delaware-incorporated company trading on Nasdaq under ticker sym | 2026-06-23 |
| Quarterly report · Q1 2026 VAXCYTE, INC. – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $260.8M in cash and equivalents plus $1.48B in short-term inv | 2026-05-06 |
| Proxy statement · Q2 2026 VAXCYTE, INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class III director nominees to serve unt | 2026-04-23 |
| Annual report FY2025 VAXCYTE, INC. – ANNUAL REPORT SUMMARY (FISCAL YEAR 2025) HEADLINE NUMBERS • Company: Clinical-stage vaccine developer (Nasdaq: PCVX) • Public float: | 2026-02-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Narrows guidance for expected VAX-31 OPUS-1 topline data Vaxcyte, Inc. announced two executive appointments and narrowed guidance on a clinical trial timeline. David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corpor | 2026-09-03 |
| 15-year drug product manufacturing and supply agreement with Patheon Vaxcyte, Inc. signed a 15-year manufacturing agreement with Patheon (owned by Thermo Fisher Scientific) on September 24, 2025, to produce its drug products at Patheon's North Carolina facili | 2025-09-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vaxcyte Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.